Compositions and methods for the treatment of meibomian gland dysfunction
AssigneeM.G. Therapeutics Ltd
InventorsYair Alster, Omer Rafaeli, K. Angela Macfarlane, Cary Reich, Shimon Amselem, Doron Friedman
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
Claims30
A method for treating meibomian gland dysfunction in a patient in need thereof, comprising topically administering to the patient a composition that reaches the eyelid margin of the patient, wherein the composition comprises a therapeutically-effective amount of at least one keratolytic agent in an ophthalmically-acceptable carrier, wherein the keratolytic agent is an inorganic selenium compound, or an organo-selenium compound.
(canceled)
(canceled)
(canceled)
A method for treating meibomian gland dysfunction in a patient in need thereof, comprising topically administering to the patient a composition that reaches the eyelid margin of the patient, wherein the composition consists of a therapeutically-effective amount of a keratolytic agent in an ophthalmically-acceptable carrier, wherein the keratolytic agent is an inorganic selenium compound, or an organo-selenium compound.
Dependencies are inferred from the claim text.